New study to see if antivirals help immunocompromised COVID patients
NCT ID NCT06683937
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will review medical records of 300 immunocompromised adults hospitalized with COVID-19 in France between June 2023 and April 2024. Researchers want to see how well antiviral drugs like nirmatrelvir/ritonavir and remdesivir work in these patients. The goal is to track their recovery and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirmatrelvir/ritonavir or remdesivir
What this could lead to
If successful, this could help doctors understand which antiviral treatments work best for immunocompromised patients with COVID-19.
What could go wrong
This is an observational study that only looks back at medical records, so it cannot prove cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOCOMPROMISED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Périgueux
Périgueux, 24000, France
Contact Email: •••••@•••••
-
CHD Vendée (La Roche sur Yon)
La Roche-sur-Yon, 85000, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
CHRU Lille
Lille, 59000, France
Contact Email: •••••@•••••
-
CHU Angers
Angers, 49000, France
Contact Email: •••••@•••••
-
CHU Caen
Caen, 14000, France
Contact Email: •••••@•••••
-
CHU Nantes
Nantes, 44000, France
Contact Email: •••••@•••••
-
CHU Nord Marseille
Marseille, 13000, France
Contact Email: •••••@•••••
-
CHU Nîmes Caremeau
Nîmes, 30000, France
Contact Email: •••••@•••••
-
CHU Poitiers
Poitiers, 86000, France
Contact Email: •••••@•••••
-
CHU Reims
Reims, 51100, France
Contact Email: •••••@•••••
-
CHU Sud Réunion
Saint-Pierre, 97410, France
Contact Email: •••••@•••••
-
CHU Toulouse
Toulouse, 31000, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Hôpital Bichat
Paris, 75018, France
Contact Email: •••••@•••••
-
Hôpital Necker-Enfants Malades
Paris, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Pasteur, Colmar
Colmar, 68000, France
Contact Email: •••••@•••••
-
Hôpital Saint-Louis
Paris, 75010, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••